Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Corcept Therapeutics (CORT)

Corcept Therapeutics Q1 revenue rises 39% to $146.8 million; raises 2024 guidance

Positive Impact 3 of 5 guidance Written later

Corcept Therapeutics reported first quarter 2024 revenue of $146.8 million, up 39 percent from a year earlier, and net income of $27.8 million, compared with $15.9 million in the first quarter of 2023. The company raised its 2024 revenue guidance to $620 million to $650 million from $600 million to $630 million, which points to stronger expected sales for the year.

Key points

  • Q1 2024 revenue of $146.8 million vs. $105.7 million in Q1 2023; diluted EPS $0.25 vs. $0.14
  • 2024 revenue guidance raised to $620 million to $650 million from $600 million to $630 million
  • Operating expenses rose to $117.3 million from $90.8 million, driven by clinical trial activity and commercial team expansion
  • Cash and investments were $451.0 million at March 31, 2024, up from $425.4 million at December 31, 2023

The filing

CompanyCorcept Therapeutics (CORT)
Form8-K, current report
Filed with the SECMay 1, 2024, 4:09 PM ET
Accession number0001628280-24-019607

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 12:57 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 01, 2024.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.